NRNP 6635 MIDTERM EXAM
LATEST MOCK PRACTICE SET
249 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NRNP 6635 MIDTERM EXAM. It contains 249 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 249 Questions
Foundations - Application - NRNP 6635 Psychiatric Mental Health Nurse Practitioner Pmhnp Graduate
All answers with rationales
,Table of Contents
Section A - Foundations OF Section B - Neurobiological Basis OF
Psychopathology AND Diagnosis Mental Disorders
Questions 1 to 63 Questions 64 to 126
Section C - Psychopharmacology Section D - MOOD Disorders AND
AND Pharmacokinetics Suicide RISK Assessment
Questions 127 to 189 Questions 190 to 249
,Section A - Foundations OF Psychopathology AND
Diagnosis
Q1.
A patient with treatment-resistant depression has failed adequate trials of two SSRIs and
one SNRI. Which neurobiological mechanism most plausibly underlies this resistance,
and which augmentation strategy specifically targets that mechanism?
A. Reduced serotonin synthesis; augment B. Overactive glutamate signaling; augment
with L-tryptophan with lamotrigine
C. Dysregulated dopamine D2 receptor D. Impaired neuroplasticity via BDNF
binding; augment with aripiprazole downregulation; augment with ketamine
Correct: D - Impaired neuroplasticity via BDNF downregulation; augment with ketamine
Rationale:Treatment-resistant depression is linked to reduced brain-derived neurotrophic
factor (BDNF) and impaired synaptic plasticity. Ketamine rapidly increases BDNF and
enhances AMPA receptor signaling, promoting synaptogenesis. Options A and B are less
evidence-based; option C is effective but targets a different mechanism (dopamine partial
agonism) and is not the most direct augmentation for neuroplasticity deficits.
Q2.
Which of the following best explains why bupropion is contraindicated in patients with
bulimia nervosa?
A. It increases the risk of serotonin B. It lowers the seizure threshold, and
syndrome due to electrolyte imbalances purging behaviors cause electrolyte
disturbances that further increase seizure
risk
C. It exacerbates purging behaviors via D. It causes orthostatic hypotension, which
dopaminergic stimulation of the vomiting is poorly tolerated in patients with bulimia
center
Correct: B - It lowers the seizure threshold, and purging behaviors cause electrolyte
disturbances that further increase seizure risk
Rationale:Bupropion lowers the seizure threshold, and bulimia nervosa often involves
electrolyte disturbances (e.g., hypokalemia, hyponatremia) from purging, which also lower the
seizure threshold. This combination significantly increases seizure risk, making bupropion
contraindicated. The other options are incorrect: bupropion does not cause serotonin
syndrome, does not directly stimulate vomiting, and orthostatic hypotension is not a primary
concern.
Page 3
, Section A - Foundations OF Psychopathology AND Diagnosis
Q3.
A patient with generalized anxiety disorder and comorbid moderate hepatic impairment
(Child-Pugh class B) requires pharmacotherapy. Which medication requires the most
significant dose reduction, and what is the primary pharmacokinetic rationale?
A. Sertraline; reduced clearance due to B. Buspirone; reduced first-pass metabolism
decreased CYP3A4 activity due to portosystemic shunting
C. Venlafaxine; increased volume of D. Lorazepam; decreased glucuronidation
distribution due to hypoalbuminemia capacity
Correct: B - Buspirone; reduced first-pass metabolism due to portosystemic shunting
Rationale:Buspirone undergoes extensive first-pass metabolism in the liver; hepatic
impairment reduces this effect, leading to increased bioavailability and higher plasma levels,
necessitating dose reduction. Sertraline is metabolized by multiple CYP enzymes, but dose
adjustment is less critical. Lorazepam is primarily renally excreted, and venlafaxine's volume
of distribution change is not the main concern.
Q4.
A patient with bipolar I disorder presents with acute mania and is unable to take oral
medications due to agitation. Which parenteral combination is most appropriate for rapid
symptom control?
A. Intramuscular haloperidol and B. Intramuscular olanzapine and
intramuscular lorazepam intramuscular benztropine
C. Intravenous valproate and intramuscular D. Intramuscular aripiprazole and oral
ziprasidone lithium
Correct: A - Intramuscular haloperidol and intramuscular lorazepam
Rationale:For acute mania requiring parenteral treatment, the combination of a typical
antipsychotic (haloperidol) and a benzodiazepine (lorazepam) provides rapid sedation and is
well-established. Intramuscular olanzapine is an option but may cause excessive sedation;
benztropine is not indicated for acute mania. Intravenous valproate is not standard, and oral
lithium is not feasible if the patient cannot take oral medications.
Q5.
A patient with major depressive disorder and a history of prolonged QTc interval (500 ms)
requires antidepressant therapy. Which of the following antidepressants is safest
regarding QTc prolongation?
A. Citalopram B. Escitalopram
C. Sertraline D. Venlafaxine
Page 4
LATEST MOCK PRACTICE SET
249 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NRNP 6635 MIDTERM EXAM. It contains 249 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 249 Questions
Foundations - Application - NRNP 6635 Psychiatric Mental Health Nurse Practitioner Pmhnp Graduate
All answers with rationales
,Table of Contents
Section A - Foundations OF Section B - Neurobiological Basis OF
Psychopathology AND Diagnosis Mental Disorders
Questions 1 to 63 Questions 64 to 126
Section C - Psychopharmacology Section D - MOOD Disorders AND
AND Pharmacokinetics Suicide RISK Assessment
Questions 127 to 189 Questions 190 to 249
,Section A - Foundations OF Psychopathology AND
Diagnosis
Q1.
A patient with treatment-resistant depression has failed adequate trials of two SSRIs and
one SNRI. Which neurobiological mechanism most plausibly underlies this resistance,
and which augmentation strategy specifically targets that mechanism?
A. Reduced serotonin synthesis; augment B. Overactive glutamate signaling; augment
with L-tryptophan with lamotrigine
C. Dysregulated dopamine D2 receptor D. Impaired neuroplasticity via BDNF
binding; augment with aripiprazole downregulation; augment with ketamine
Correct: D - Impaired neuroplasticity via BDNF downregulation; augment with ketamine
Rationale:Treatment-resistant depression is linked to reduced brain-derived neurotrophic
factor (BDNF) and impaired synaptic plasticity. Ketamine rapidly increases BDNF and
enhances AMPA receptor signaling, promoting synaptogenesis. Options A and B are less
evidence-based; option C is effective but targets a different mechanism (dopamine partial
agonism) and is not the most direct augmentation for neuroplasticity deficits.
Q2.
Which of the following best explains why bupropion is contraindicated in patients with
bulimia nervosa?
A. It increases the risk of serotonin B. It lowers the seizure threshold, and
syndrome due to electrolyte imbalances purging behaviors cause electrolyte
disturbances that further increase seizure
risk
C. It exacerbates purging behaviors via D. It causes orthostatic hypotension, which
dopaminergic stimulation of the vomiting is poorly tolerated in patients with bulimia
center
Correct: B - It lowers the seizure threshold, and purging behaviors cause electrolyte
disturbances that further increase seizure risk
Rationale:Bupropion lowers the seizure threshold, and bulimia nervosa often involves
electrolyte disturbances (e.g., hypokalemia, hyponatremia) from purging, which also lower the
seizure threshold. This combination significantly increases seizure risk, making bupropion
contraindicated. The other options are incorrect: bupropion does not cause serotonin
syndrome, does not directly stimulate vomiting, and orthostatic hypotension is not a primary
concern.
Page 3
, Section A - Foundations OF Psychopathology AND Diagnosis
Q3.
A patient with generalized anxiety disorder and comorbid moderate hepatic impairment
(Child-Pugh class B) requires pharmacotherapy. Which medication requires the most
significant dose reduction, and what is the primary pharmacokinetic rationale?
A. Sertraline; reduced clearance due to B. Buspirone; reduced first-pass metabolism
decreased CYP3A4 activity due to portosystemic shunting
C. Venlafaxine; increased volume of D. Lorazepam; decreased glucuronidation
distribution due to hypoalbuminemia capacity
Correct: B - Buspirone; reduced first-pass metabolism due to portosystemic shunting
Rationale:Buspirone undergoes extensive first-pass metabolism in the liver; hepatic
impairment reduces this effect, leading to increased bioavailability and higher plasma levels,
necessitating dose reduction. Sertraline is metabolized by multiple CYP enzymes, but dose
adjustment is less critical. Lorazepam is primarily renally excreted, and venlafaxine's volume
of distribution change is not the main concern.
Q4.
A patient with bipolar I disorder presents with acute mania and is unable to take oral
medications due to agitation. Which parenteral combination is most appropriate for rapid
symptom control?
A. Intramuscular haloperidol and B. Intramuscular olanzapine and
intramuscular lorazepam intramuscular benztropine
C. Intravenous valproate and intramuscular D. Intramuscular aripiprazole and oral
ziprasidone lithium
Correct: A - Intramuscular haloperidol and intramuscular lorazepam
Rationale:For acute mania requiring parenteral treatment, the combination of a typical
antipsychotic (haloperidol) and a benzodiazepine (lorazepam) provides rapid sedation and is
well-established. Intramuscular olanzapine is an option but may cause excessive sedation;
benztropine is not indicated for acute mania. Intravenous valproate is not standard, and oral
lithium is not feasible if the patient cannot take oral medications.
Q5.
A patient with major depressive disorder and a history of prolonged QTc interval (500 ms)
requires antidepressant therapy. Which of the following antidepressants is safest
regarding QTc prolongation?
A. Citalopram B. Escitalopram
C. Sertraline D. Venlafaxine
Page 4
